Merck Tbk. vs Paramita Bangun Sarana Tbk. — how do they compare? Merck Tbk. trades at Rp3,840 (market cap 1.7T, 37.6K 24h volume), while Paramita Bangun Sarana Tbk. trades at Rp755 (market cap 2.19T, 877.3K 24h volume). The key difference: Paramita Bangun Sarana Tbk. is the larger of the two by market cap, and Paramita Bangun Sarana Tbk. is more actively traded (877.3K versus 37.6K). Which is the better fit depends on your goals.
| MERK | PBSA | |
|---|---|---|
Market Cap | 1.7T | 2.19T |
Volume | 37.6K | 877.3K |
Lot | 376 | 8.77K |
Turnover | 144.47M | 649.02M |
Average Price | 3,842.23 | 739.79 |
Value | 144.47M | 649.02M |
Indicative Equilibrium Price | 3,840 | 755 |
Indicative Equilibrium Volume | 7 | 20 |
Trailing returns across standard periods
Latest headlines on both assets
PT Merck Tbk (the Company) is domiciled in Indonesia and located at Jl. TB Simatupang No. 8, Pasar Rebo, East Jakarta, was established in framework of Law No. 1 of 1967 and Law No. 11 of 1970 on foreign capital investment by deed of notary public Eliza Pondaag, SH dated 14 October 1970 No. 29. PT Merck Indonesia is a member of the Merck International Group. The company produces pharmaceutical products with production facility in East Jakarta. It commenced its operation in 1974 in manufacturing medical products, such as Songobian and Neurobion.
Read more on MERK →PT. Paramita Bangun Sarana Tbk (the Company) was established based on the Notarial Deed No. 33 of Lenny Janis Ishak, S.H., dated November 27, 2002.
Read more on PBSA →